The US Genetic Testing Market encompasses genetic testing products and services used in reproductive health, cancer screening, carrier testing, diagnostic testing, and predictive healthcare. According to Market Research Future, diagnostic testing recorded the highest application valuation in 2024 at USD 1.2 billion.

Genetic testing technologies include whole exome sequencing, whole genome sequencing, panel tests, single-gene tests, and non-invasive prenatal testing. Whole exome sequencing holds the largest share among the testing types covered, while whole genome sequencing is projected to reach USD 4.76 billion by 2035.

Clinical laboratories are the largest end-user group, while hospitals are expanding their role as genetic testing becomes more closely connected with routine clinical practice. Research institutions and homecare settings represent additional areas of use, particularly as testing technologies and access models continue to evolve.

Key companies identified in the report include Illumina, Thermo Fisher Scientific, Roche, Myriad Genetics, 23andMe, Genomic Health, Invitae, Fulgent Genetics, and Color Genomics. Competition is influenced by sequencing innovation, testing portfolios, partnerships, digitalization, and the growing emphasis on personalized medicine.